[en] BACKGROUND: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability. AIMS: To identify the factors associated with obese and overweight patients with IBD, including IBD-related disability. PATIENTS AND METHODS: In this cross-sectional study, we included 1704 consecutive patients with IBD in 42 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif (GETAID) using a 4-page questionnaire. Factors associated with obesity and overweight were assessed using univariate and multivariate analyses (odds ratios (ORs) are provided with 95% confidence intervals). RESULTS: The prevalence rates of overweight and obesity were 24.1% and 12.2%, respectively. Multivariable analyses were stratified by age, sex, type of IBD, clinical remission and age at diagnosis of IBD. Overweight was significantly associated with male sex (OR = 0.52, 95% CI [0.39-0.68], p < 0.001), age (OR = 1.02, 95% CI [1.01-1.03], p < 0.001) and body image subscore (OR = 1.15, 95% CI [1.10-1.20], p < 0.001) (Table 2). Obesity was significantly associated with age (OR = 1.03, 95% CI [1.02-1.04], p < 0.001), joint pain subscore (OR = 1.08, 95% CI [1.02-1.14], p < 0.001) and body image subscore (OR = 1.25, 95% CI [1.19-1.32], p < 0.001) (Table 3). CONCLUSION: The increasing prevalence of overweight and obesity in patients with IBD is associated with age and poorer body image. A holistic approach to IBD patient care should be encouraged to improve IBD-related disability and to prevent rheumatological and cardiovascular complications.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Bacha, Rose Al; Department of Gastroenterology, Bicetre University Hospital, Universite Paris
Bouhnik, Yoram; Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital,
Serrero, Melanie; Hôpital Nord, Centre d'investigation Clinique Marseille Nord, Université
Filippi, Jerome; Department of Gastroenterology and Clinical Nutrition, CHU of Nice, University
Roblin, Xavier; Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Etienne,
Bourrier, Anne; Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine, UPMC Université
Bouguen, Guillaume; Department of Gastroenterology, CHU Rennes and University of Rennes, NUMECAN
Franchimont, Denis; Department of Gastroenterology, Hôpital Erasme, Laboratoire de Gastroenterologie
Savoye, Guillaume; Department of Gastroenterology, Rouen University Hospital, Rouen, France.
Buisson, Anthony; Department of Hepato-Gastroenterology, University Hospital Estaing of
Louis, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Nancey, Stephane; Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon and
Abitbol, Vered; Department of Gastroenterology, Cochin University Hospital, Paris, France.
Reimund, Jean-Marie; Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpitaux
Heymsfield, SB, Wadden, TA, Mechanisms, pathophysiology, and management of obesity. N Engl J Med 376 (2017), 254–266.
Boutari, C, Mantzoros, CS., A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism, 133, 2022, 155217.
Singh, S, Dulai, PS, Zarrinpar, A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol 14 (2017), 110–121.
Dotan, I, Ron, Y, Yanai, H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 20 (2014), 2247–2259.
Brandse, JF, Mould, D, Smeekes, O, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis 23 (2017), 650–660.
Levine, LJ, Gaidos, JKJ, Proctor, DD, et al. Effect of obesity on vedolizumab response in inflammatory bowel disease. Ann Gastroenterol 35 (2022), 275–280.
Peyrin-Biroulet, L, Cieza, A, Sandborn, WJ, et al. Disability in inflammatory bowel diseases: developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflamm Bowel Dis 16 (2010), 15–22.
International classification of functioning, disability and health (ICF). 2001, WHO, Geneva.
Tannoury, J, Nachury, M, Martins, C, et al. Determinants of IBD-related disability: a cross-sectional survey from the GETAID. Aliment Pharmacol Ther, 2021.
Jain, A, Nguyen, NH, Proudfoot, JA, et al. Impact of obesity on disease activity and patient-reported outcomes measurement information system (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol 114 (2019), 630–639.
Tadbiri, S, Nachury, M, Bouhnik, Y, et al. The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease. J Crohns Colitis, 2020.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser, 894, 2000 i-xii, 1-253.
Blüher, M., Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 15 (2019), 288–298.
Chan, SSM, Chen, Y, Casey, K, et al. Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol 20 (2022), 1048–1058.
Milajerdi, A, Abbasi, F, Esmaillzadeh, A., A systematic review and meta-analysis of prospective studies on obesity and risk of inflammatory bowel disease. Nutr Rev 80 (2022), 479–487.
Rahmani, J, Kord-Varkaneh, H, Hekmatdoost, A, et al. Body mass index and risk of inflammatory bowel disease: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. Obes Rev 20 (2019), 1312–1320.
Gu, P, Luo, J, Kim, J, et al. Effect of obesity on risk of hospitalization, surgery, and serious infection in biologic-treated patients with inflammatory bowel diseases: a CA-IBD cohort study. Am J Gastroenterol 117 (2022), 1639–1647.
Losurdo, G, La Fortezza, RF, Iannone, A, et al. Prevalence and associated factors of obesity in inflammatory bowel disease: a case-control study. World J Gastroenterol 26 (2020), 7528–7537.
Jura, M, Kozak, LP., Obesity and related consequences to ageing. Age, 38, 2016, 23.
Starr, ME, Evers, BM, Saito, H., Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A 64 (2009), 723–730.
Grotle, M, Hagen, KB, Natvig, B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord, 9, 2008, 132.
Messier, SP, Mihalko, SL, Legault, C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 310 (2013), 1263–1273.
Kolotkin, RL, Andersen, JR., A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes 7 (2017), 273–289.
Harbord, M, Annese, V, Vavricka, SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10 (2016), 239–254.
Saha, S, Zhao, Y-Q, Shah, SA, et al. Body image dissatisfaction in patients with inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 345–352.
McDermott, E, Mullen, G, Moloney, J, et al. Body image dissatisfaction: clinical features, and psychosocial disability in inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 353–360.
Beese, SE, Harris, IM, Dretzke, J, et al. Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review. BMJ Open Gastroenterol, 6, 2019, e000255.
